Corning Jerry Pharmaceutical-B announced that the company previously disclosed that JSKN021 was approved for phase I clinical trials in China and completed the first patient administration in June 2026; the announcement stated that the FDA has approved the JSKN021 phase I clinical study IND, marking the official start of overseas clinical development; at present, clinical research in China is progressing in an orderly manner, and initial curative effects have been observed during the climbing process.

Corning Jerry Pharmaceutical-B announced that the company previously disclosed that JSKN021 was approved for phase I clinical trials in China and completed the first patient administration in June 2026; the announcement stated that the FDA has approved the JSKN021 phase I clinical study IND, marking the official start of overseas clinical development; at present, clinical research in China is progressing in an orderly manner, and initial curative effects have been observed during the climbing process.